The German Business Panel (GBP) is a data infrastructure that periodically surveys executives and key decision-makers in a representative sample of German firms, eliciting their perceptions, views, and expectations. The primary objective of the longitudinal panel study is to generate evidence on the role of accounting and tax regulation for companies. It is part of the Collaborative Research Center (SFB/TRR) Project-ID 403041268 – TRR 266 Accounting for Transparency. The 2020 GBP Covid-19 Survey focusses on the impact of the health crisis on firm´s key outcomes like revenues, profits, as well as perceptions, responses, and plans of decision makers. Questions elicit manager and firm characteristics, as well as perceptions on economic uncertainty, firm survival, government economic policy, take-up of government support, and managerial strategies to responds to the crisis as well as future investment and employment plans. The questionnaire includes various instruments with experimental variation. More information is available at gbpanel.org. The 2020 GBP Covid-19 Survey was conducted from July-October 2020 and from November-February 2021 on a rolling basis among a representative sample of decision makers of legally independent private and public businesses with economic activity in the Federal Republic of Germany. For each of the two survey periods, the sampling involved a two-stage procedure. First, a simple random sample was drawn, which was then in a second step randomly allocated according to a contact protocol to generate a rolling cross-section. The two rolling cross-sections together form a rolling panel. The survey was conducted by the German Business Panel team, Mannheim. Interviews were conducted using online computer-assisted web interviewing (CAWI). Parts of the interviews involved computer assisted telephone interviewing (CATI).

The aim of the special survey of the GESIS panel on the outbreak of the corona virus SARS-CoV-2 in Germany was to collect timely data on the effects of the corona crisis on people´s daily lives. The study focused on questions of risk perception, risk minimization measures, evaluation of political measures and their compliance, trust in politics and institutions, changed employment situation, childcare obligations, and media consumption. Due to the need for timely data collection, only the GESIS panel sub-sample of online respondents was invited (about three quarters of the sample). Since, due to time constraints, respondents could only participate in the online survey but not by mail, the results cannot be easily transferred to the overall population. Further longitudinal surveys on Covid-19 with the entire sample of the GESIS panel are planned for 2020.

Topics: Risk perception: Probability of events related to corona infection in the next two months (self, infection of a person from close social surrondings, hospital treatment, quarantine measures regardless of whether infected or not, infecting other people)

Risk minimization: risk minimization measures taken in the last seven days (avoided certain (busy) places, kept minimum distance to other people, adapted school or work situation, quarantine due to symptoms or without symptoms, washed hands more often, used disinfectant, stocks increased, reduced social interactions, worn face mask, other, none of these measures).

Evaluation of the effectiveness of various policy measures to combat the further spread of corona virus (closure of day-care centres, kindergartens and schools, closure of sports facilities, closure of bars, cafés and restaurants, closure of all shops except supermarkets and pharmacies, ban on visiting hospitals, nursing homes and old people´s homes, curfew for persons aged 70 and over or people with health problems or for anyone not working in the health sector or other critical professions (except for basic purchases and urgent medical care).

Curfew compliance or refusal: Willingness to obey a curfew vs. refusal; reasons for the compliance with curfew (social duty, fear of punishment, protection against infection, fear of infecting others (loved ones, infecting others in general, a risk group); reasons for refusal of curfew (restrictions too drastic or not justified, other obligations, does not stop the spread, not affected by the outbreak, boring at home, will not be punished).

Evaluation of the effectiveness of various government measures (medical care, restrictions on social life such as closure of public facilities and businesses, reduction of economic damage, communication with the population).

Trust in politics and institutions with regard to dealing with the coronavirus (physician, local health authority, local and municipal administration, Robert Koch Institute (RKI), Federal Government, German Chancellor, Ministry of Health, World Health Organization (WHO), scientists).

Changed employment situation: employment status at the beginning of March; change in occupational situation since the spread of coronavirus: dependent employees: number of hours reduced, number of hours increased, more home office, leave of absence with/ without continued wage payment , fired, no change; self-employed: working hours reduced, working hours increased, more home office, revenue decreased, revenue increased, company temporarily closed by the authorities, company temporarily voluntarily closed, financial hardship, company permanently closed or insolvent, no change.

Childcare: children under 12 in the household; organisation of childcare during the closure of day-care centres, kindergartens and schools (staying at home, partner stays at home, older siblings take care, grandparents are watching, etc.)

Media consumption on Corona: information sources used for Corona (e.g. nationwide public or private television or radio, local public or private television or radio, national newspapers or local newspapers, Facebook, other social media, personal conversations with friends and family, other, do not inform myself on the subject); frequency of Facebook usage; information about Corona obtained from regional Facebook page or regional Facebook group.

Demography: sex; age (categorized); education (categorized); intention to vote and choice of party (Sunday question); Left-right self-assessment; marital status; size of household.

Additionally coded: Respondent ID;...

The German construction industry expanded by 3.6% in real terms in 2019, driven by public and private sector investments in both building and civil engineering works. Even before the Coronavirus (COVID-19) outbreak, the country’s construction industry remained strong, with the residential sector supporting the industry with an increase in building permits by 1.8% in 2019, and the government’s efforts to ease the housing shortage. Read More

In 2024 thus far, there were around *** million car sharing users in Germany. This was another noticeable increase compared to roughly **** million the year before. Figures increased almost annually during the specified timeline. The break in 2020 was due to the restrictions on mobility and travel during the coronavirus (COVID-19) pandemic. How does it work? The term car sharing means the organized communal use of one or more cars, and is one example of a growing sharing economy around the world. Car sharing may be a practical solution for city dwellers not looking to buy a car, who drive only occasionally. Aside from details pertaining to individual car sharing companies, generally, the system works the same way anywhere. A company provides a certain number of cars, users typically download an app to their smartphone to be able to use the service (though they might also book a vehicle via a website or a phone call). The car is then opened with the respective app, customer card or a key. Billing is based either on minutes, distance covered, both or a flat rate. Cars are used by multiple customers. Private car sharing is also an option. Rural areas are usually not covered. Conquering consumers Car sharing is still a fairly young market in Germany, with strong growth potential, though not without challenges. Interest in car sharing has waned somewhat in recent years, judging by surveys. In 2023, around * million people in Germany confirmed their interest, compared to roughly *** million the year before. Meanwhile, the number of car sharing companies has increased steadily in recent years, with *** operating in the country thus far in 2024.

Das German Business Panel (GBP) ist eine Dateninfrastruktur, die regelmäßig Führungskräfte und wichtige Entscheidungsträger in einer repräsentativen Stichprobe deutscher Unternehmen befragt und deren Wahrnehmungen, Ansichten und Erwartungen erhebt. Das primäre Ziel der Längsschnitt-Panel-Studie ist es, Evidenz über die Rolle von Rechnungslegungs- und Steuerregulierung für Unternehmen zu generieren. Sie ist Teil des Sonderforschungsbereichs (SFB/TRR) Projekt-ID 403041268 - TRR 266 Rechnungslegung für Transparenz. Die 2020 GBP Covid-19 Umfrage konzentriert sich auf die Auswirkungen der Gesundheitskrise auf die wichtigsten Unternehmensergebnisse wie Umsätze und Gewinne, sowie auf die Wahrnehmungen, Reaktionen und Pläne der Entscheidungsträger. Fragen erheben Manager- und Firmencharakteristika sowie Wahrnehmungen zu wirtschaftlicher Unsicherheit, Firmenüberleben, staatlicher Wirtschaftspolitik, Inanspruchnahme von staatlicher Unterstützung und Managementstrategien als Reaktion auf die Krise sowie zukünftige Investitions- und Beschäftigungspläne. Der Fragebogen enthält verschiedene Instrumente mit experimenteller Variation. Weitere Informationen finden Sie unter gbpanel.org. Die GBP-Covid-19-Umfrage 2020 wurde von Juli bis Oktober 2020 und von November bis Februar 2021 auf rollierender Basis unter einer repräsentativen Stichprobe von Entscheidungsträgern rechtlich selbständiger privater und öffentlicher Unternehmen mit wirtschaftlicher Tätigkeit in der Bundesrepublik Deutschland durchgeführt. Die Stichprobenziehung erfolgte für jeden der beiden Erhebungszeiträume in einem zweistufigen Verfahren. Zunächst wurde eine einfache Zufallsstichprobe gezogen, die dann in einem zweiten Schritt nach einem Kontaktprotokoll zufällig verteilt wurde, um einen rollierenden Querschnitt zu erzeugen. Die beiden rollierenden Querschnitte bilden zusammen ein rollierendes Panel. Die Befragung wurde durch das Team des Deutschen Wirtschaftspanels, Mannheim, durchgeführt. Die Interviews wurden mittels computergestütztem Online-Web-Interviewing (CAWI) durchgeführt. Teile der Interviews wurden mittels computergestützter Telefonbefragung (CATI) durchgeführt. The German Business Panel (GBP) is a data infrastructure that periodically surveys executives and key decision-makers in a representative sample of German firms, eliciting their perceptions, views, and expectations. The primary objective of the longitudinal panel study is to generate evidence on the role of accounting and tax regulation for companies. It is part of the Collaborative Research Center (SFB/TRR) Project-ID 403041268 – TRR 266 Accounting for Transparency. The 2020 GBP Covid-19 Survey focusses on the impact of the health crisis on firm´s key outcomes like revenues, profits, as well as perceptions, responses, and plans of decision makers. Questions elicit manager and firm characteristics, as well as perceptions on economic uncertainty, firm survival, government economic policy, take-up of government support, and managerial strategies to responds to the crisis as well as future investment and employment plans. The questionnaire includes various instruments with experimental variation. More information is available at gbpanel.org. The 2020 GBP Covid-19 Survey was conducted from July-October 2020 and from November-February 2021 on a rolling basis among a representative sample of decision makers of legally independent private and public businesses with economic activity in the Federal Republic of Germany. For each of the two survey periods, the sampling involved a two-stage procedure. First, a simple random sample was drawn, which was then in a second step randomly allocated according to a contact protocol to generate a rolling cross-section. The two rolling cross-sections together form a rolling panel. The survey was conducted by the German Business Panel team, Mannheim. Interviews were conducted using online computer-assisted web interviewing (CAWI). Parts of the interviews involved computer assisted telephone interviewing (CATI).

Snapshot img

Vaccine Research Market Size 2024-2028

The vaccine research market size is forecast to increase by USD 21.4 billion, at a CAGR of 10.84% between 2023 and 2028.

Major Market Trends & Insights

North America dominated the market and accounted for a 44% growth during the forecast period.
By the End-user - Public segment was valued at USD 12.10 billion in 2022
By the Age Group - Pediatric segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 170.05 billion
Market Future Opportunities: USD 21.40 billion
CAGR : 10.84%
North America: Largest market in 2022

Market Summary

The market is a dynamic and innovative sector, driven by advancements in biotechnology and pharmaceuticals. According to recent reports, the global vaccine market size was valued at over USD50 billion in 2020, with a significant increase in investments in research and development. This growth can be attributed to the ongoing efforts to address various infectious diseases, including those that pose a significant public health threat. Notably, the adoption of artificial intelligence (AI) and machine learning (ML) technologies has accelerated vaccine research, enabling faster identification of potential vaccines and reducing the time-to-market. For instance, AI algorithms can analyze vast amounts of data from clinical trials, predicting potential side effects and optimizing dosages.
Furthermore, ML models can identify patterns in disease outbreaks, helping researchers to focus their efforts on developing vaccines for the most pressing health concerns. Despite these advancements, the high cost of vaccine research, development, and manufacturing remains a significant challenge. However, collaborations between public and private entities, as well as government funding, are helping to mitigate these costs and ensure that vaccines remain accessible to those who need them most. Overall, the market continues to evolve, driven by the need to address new and emerging health threats and improve global health outcomes.

What will be the Size of the Vaccine Research Market during the forecast period?

Explore market size, adoption trends, and growth potential for vaccine research market Request Free Sample

The market encompasses the development, manufacturing, and testing of various vaccine types, including live attenuated, RNA, recombinant, subunit, conjugate, peptide, inactivated, and virus-like particle vaccines. Two significant milestones in this dynamic industry are the completion of phase 3 trials and the initiation of process validation. For instance, in phase 3 trials, cohort studies involving thousands of participants assess vaccine efficacy and safety. Simultaneously, process validation ensures the consistency and reliability of manufacturing processes for vaccine production. Live attenuated vaccines, such as those based on the measles virus, have historically accounted for a substantial market share.
However, the advent of RNA vaccines, like those developed for COVID-19, has introduced innovative technologies and expanded the vaccine development pipeline. In 2020, over 200 vaccines were in various stages of clinical development, with approximately 50 in phase 3 trials. This underscores the continuous evolution and growth of the market, driven by ongoing research in adjuvants, immune profiling, immune modulation, and safety assessments.

How is this Vaccine Research Industry segmented?

The vaccine research industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Public
  Private


Age Group

  Pediatric
  Adult


Technology

  Recombinant Vaccines
  mRNA Vaccines
  Subunit Vaccines
  Live-Attenuated Vaccines
  Inactivated Vaccines
  Viral Vector Vaccines
  Conjugate Vaccines
  Toxoid Vaccines
  Adjuvants


Disease Type

  Infectious Diseases
  Cancer
  Autoimmune Diseases
  Allergies
  Neurological Disorders


Research Phase

  Preclinical Research
  Clinical Trials (Phase I, Phase II, Phase III)
  Discovery & Development


End-User

  Pharmaceutical & Biotechnology Companies
  Academic & Research Institutions
  Contract Research Organizations (CROs)
  Government Agencies


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa

    Egypt
    KSA
    Oman
    UAE


  APAC

    China
    India
    Japan


  South America

    Argentina
    Brazil


  Rest of World (ROW)

By End-user Insights

The public segment is estimated to witness significant growth during the forecast period.

The market is driven by the ongoing global health crisis and the need for effective vaccines against var